DIFFERENT STROKES FOR DIFFERENT FOLKS!!

Similar documents
[(PHY-3a) Initials of MD reviewing films] [(PHY-3b) Initials of 2 nd opinion MD]

CEREBRO VASCULAR ACCIDENTS

/ / / / / / Hospital Abstraction: Stroke/TIA. Participant ID: Hospital Code: Multi-Ethnic Study of Atherosclerosis

Cryptogenic Strokes: Evaluation and Management

Overview of Stroke: Etiologies, Demographics, Syndromes, and Outcomes. Alex Abou-Chebl, MD, FSVIN Medical Director, Stroke Baptist Health Louisville

What is the appropriate evaluation of cryptogenic stroke, and when is a hypercoagulability work-up needed? David E. Thaler, MD, PhD, FAHA

Cryptogenic Stroke: Finding Light in the Darkness

Patent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS

EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism. Luigi P. Badano, MD, FESC

PFO Management update

ACUTE CENTRAL PERIFERALEMBOLISM

Neuropathology lecture series. III. Neuropathology of Cerebrovascular Disease. Physiology of cerebral blood flow

MD SUBTYPE ADJUDICATION VARIABLE DEFINITIONS MANUAL The following is a list of variables and how to complete each one:

MEET 2007: Evaluation and treatment of the stroke and TIA patient for the non-neurointerventionist. neurointerventionist

TIA: Updates and Management 2008

Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do?

How to Evaluate Patients with Cryptogenic Stroke

Stroke/TIA. Tom Bedwell

Speakers. 2015, American Heart Association 1

How Can We Properly Manage Patients With Stroke of Undetermined Origin?

Management and Investigation of Ischemic Stroke By Etiology

Karl Meisel, MD MA Director of Stroke Clinic University of California San Francisco


DEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE. Matthew Starr, MD Stroke Attending

Permanent foramen ovale: when to close?

Advances in Prevention and Treatment of Stroke: What Every Primary Care Physician Needs to Know. Case 1 4/5/11. What treatment should you initiate?

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

Cerebrovascular Disease

Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece

Cerebrovascular Disease

Guiding Secondary Stroke Prevention through Evaluation of Ischemic Stroke Etiology

Cryptogenic Stroke: A logical approach to a common clinical problem

True cryptogenic stroke

Symptoms of small vessel strokes. Small Vessel stroke. What is this? Treatment. Large Vessel stroke 6/1/2018

Cerebrovascular Disorders. Blood, Brain, and Energy. Blood Supply to the Brain 2/14/11

Shawke A. Soueidan, MD. Riverside Neurology & Sleep Specialists

Comparison of Five Major Recent Endovascular Treatment Trials

Cryptogenic Stroke: What Don t We Know. Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare

Nicolas Bianchi M.D. May 15th, 2012

2018 Update in Diagnosis and Management of Stroke

2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.

CAROTID DEBATE High-Grade Asymptomatic Disease Should Be Repaired Selectively; Medical Management is NOT Enough

Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)

Stroke Topics. Advances in the Prevention and Treatment of Stroke. Non-Contrast Head CT. Patient 1-68 yo man

2015 Update in Diagnosis and Management of Stroke

Neuroanatomy of a Stroke. Joni Clark, MD Professor of Neurology Barrow Neurologic Institute

Brain Attack. Strategies in the Management of Acute Ischemic Stroke: Neuroscience Clerkship. Case Medical Center

Stroke Case Studies. Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow

What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen

The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging

Dr Ben Turner. Consultant Neurologist and Honorary Senior Lecturer Barts and The London NHS Trust London Bridge Hospital

TIA triage in Not all that glitters is gold

A CASE OF RECURRENT ALTERNATING TRANSIENT HEMIPARESIS Dr. Shunmuga Arumugasamy.S DNB Resident Railway Hospital, Perambur.

Small Vessel Stroke. Domenico Inzitari Careggi University Hospital Florence (Italy)

Identifying Cerebrovascular Disorders. Wengui Yu, MD, PhD Department of Neurology, University of California, Irvine

The Importance of Middle Cerebral Artery Stenosis In Patients With A Lacunar Infarction In The Carotid Artery Territory

Clinical Indications for Echocardiography

ACUTE STROKE. Internal Medicine Lecture July 17, 2018

CVA. Alison Atwater PA-C

Alan Barber. Professor of Clinical Neurology University of Auckland

10/19/12. Uncommon Causes of Stroke. José Biller, MD, FACP, FAAN, FAHA Disclosures. Dr. Biller has no disclosures to report

Vivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine

Thrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE

Vessel Wall Imaging of Intracranial Arterial Disease Commercial Interests

Echocardiography after stroke - where to look

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

Non-commercial use only

Cerebral Vascular Diseases. Nabila Hamdi MD, PhD

Guidelines for management of stroke in childhood

Secondary Prevention of. Stroke: What a GP needs to know

Ischemic stroke: management, prevention and follow up. Amit Kansara MD Providence Stroke Center Providence Brain and Spine Institute

Disclosures. Sneddon Syndrome: Untangling the Web. Case Presentation. MRI head w/ and w/o contrast. Further Workup. Further Workup 10/26/2017

Are there still any valid indications for thrombophilia screening in DVT?

Seek and Ye Shall Find: Surprising Findings When Using the ILR-LINQ

Clinical Prediction Rule for Treatment Change Based on Echocardiogram Findings in Transient Ischemic Attack and Non-Disabling Stroke

Watchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg

2014 Update in Diagnosis and Management of Stroke

I, (Issam Moussa) DO NOT have a financial interest/arrangement t/ t or affiliation with one or more organizations that could be perceived as a real

Appendix. Appendix TOAST Abstraction Manual. TOAST Medical Record Abstraction Manual

Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective

GERIATRICS CASE PRESENTATION

Detailed Order Request Checklists for Cardiology

Rahul Jhaveri, M.D. The Heart Group of Lancaster General Health

Supplemental Figures and Legends

Modena, 6 novembre Heart and Brain. Paolo Bovi

Moyamoya Disease A Vasculopathy and an Uncommon Cause of Recurrent Cerebrovascular Accidents

An Introduc+on to Stroke

DISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University

Critical Review Form Therapy

Disclosure Statement: Dr. Knoefel has nothing to disclose

FORAME OVALE PERVIO E ICTUS CRIPTOGENETICO: Dimensione del problema. Roberto Mantovan, MD, PhD U.O. Cardiologia Ospedale M.

M. Edip Gurol, MD, MSc Stroke Service/Neurology, Massachusetts General Hospital, Harvard Medical School

Stroke 101. Maine Cardiovascular Health Summit. Eileen Hawkins, RN, MSN, CNRN Pen Bay Stroke Program Coordinator November 7, 2013

INSTITUTE OF NEUROSURGERY & DEPARTMENT OF PICU

Stroke School for Internists Part 1

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Stroke and ASA / FO REBUTTAL

Sixth Annual Intensive Update in Neurology 9/15-16/2016. W Tom Kushner DO Swedish Stroke Clinic Neurohospitalist

Transcription:

DIFFERENT STROKES FOR DIFFERENT FOLKS!! Identifying Stroke Subtypes SWAROOP PAWAR M.D., MPH. Vascular Neurologist UMG Neuroscience Associates Greenville Health System

None Disclosures

Outline Stroke, TIA and Mimics Ischemic Stroke Subtypes Cryptogenic Stroke Adequate Stroke Workup Workup specific to stroke type Conclusion

Stroke Definition Stroke is a sudden focal neurological deficit, attributed to a vascular cause Ischemic (lack of blood flow) > 85% Hemorrhagic < 15%, including both intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH) sudden onset of focal brain dysfunction-- hallmark of stroke

Stroke Mimics Seizure (post-ictal paralysis) Other structural lesions (tumor, abscess, subdural hematoma, encephalitis, etc.) Metabolic derangements (hypo/hyperglycemia) Migraine Psychiatric disease

Transient ischemic attack (TIA) sudden-onset focal neurologic deficit resolving within 24 hours (traditional definition) attributed to ischemia/vascular cause duration usually minutes to a few hours transient focal neurologic deficit due to ischemia without evidence of infarction by imaging or pathologic study (new definition)

TIA is a warning of stroke! High risk of stroke in the immediate future: 9.2% within 90 days 5.5% within 7 days 3.9 % within 48 hours 20% of patients with strokes died Diagnostic evaluation the same as for ischemic stroke Neuroimaging (MRI) now recommended to rule out subclinical stroke Johnston SC et al. Lancet 2007 :369:283-92.

Subtypes

STROKE Ischemic (85%) Hemorrhagic conversion of ischemic infarct Hemorrhagic (15%) Arterial Venous sinus thrombosis ICH SAH Cardioembolism (20%) HTN Aneurysmal Large vessel (20%) Amyloid angiopathy Non-aneurysmal Lacunar (25%) AVM Cryptogenic (30%) Other Unusual cause (5%)

Large artery atherothromboembolism Extracranial Internal carotid artery (ICA) Common carotid artery (CCA) Vertebral artery (VA) Intracranial Internal carotid artery (ICA) Middle cerebral artery (MCA) Anterior cerebral artery (ACA) Vertebral artery (VA) Basilar artery (BA) Posterior cerebral artery (PCA)

Extra & Intra-cranial stenosis Stroke due to artery-artery embolism more than hypoperfusion

Cardioembolism

Cardioembolic Sources High risk Mechanical valve Mitral stenosis with AFib Atrial fibrillation Sick sinus syndrome Left atrial appendage thrombus Recent MI (<4 weeks) LV thrombus Dilated cardiomyopathy Akinetic LV segment Atrial myxoma Infective endocarditis Medium/low risk Mitral valve prolapse Mitral annular calcification Mitral stenosis without Afib Atrial septal aneurysm Patent foramen ovale Atrial flutter Bioprosthetic valve Nonbacterial thrombotic endocarditis Congestive heart failure Hypokinetic LV segment MI (>4 weeks, <6 mo.)

Not all cardioembolic strokes Rx with anti-coagulation! Endocarditis - antibiotics,? surgery Atrial myxoma - surgery Figure 1. Transesophageal echocardiogram demonstrating multiple mitral valve vegetations (arrows). Associated findings included mitral valve prolapse with severe mitral valve regurgitation (Figure 1, A) and moderate posterior mitral annular calcification with mobile vegetation (arrowhead, Figure 1, B).

Small Vessel Occlusive Disease Lacunar Stroke Small infarcts involving subcortical structures of the brain: Internal capsule, basal ganglia, thalamus Refers to size (<15 mm), not etiology Lipohyalinosis of penetrating end-arteries off major intracranial vessels (e.g. MCA lenticulostriates) Microatheroma Emboli

Lacunar Infarcts

Lacunar Syndromes Pure motor Pure sensory Sensorimotor Ataxic hemiparesis Clumsy hand-dysarthria Hemiballismus-hemichorea

Is This a Lacunar Stroke?

Small vessel strokes accounted for almost half of the events in our study (48%) with a subset of these in the distribution of small penetrator vessels (23%).

25 symptomatic lacunar infarcts were studied... Four types of penetrating artery occlusion were found: (1) occlusion by an atheroma with superimposed thrombus (2) blockage of the mouth of a penetrating artery by atheroma in the wall of the parent artery; (3) dissection in the wall of the parent artery, causing obstruction of the penetrator; and (4) lipohyalinosis. In 5 of the 25 lacunes, the artery appeared to be essentially normal and fully patent, a finding consistent with microembolism. The riddle of the nature and cause of lacunes had been solved. Stroke, 2001

Other KNOWN causes of stroke (~5%) Dissection Vasculitis (Infec/Inflamm) Systemic Primary CNS angiitis Drug-associated vasculopathy RCVS Moya-moya Genetic Sickle cell disease Fabry s disease CADASIL Hypercoagulable states Systemic malignancy Antiphospholipid antibodies Heritable Factor V Leiden Prothrombin mutation Protein C, S, antithrombin III deficiency Pregnancy, OCP, HRT Polycythemia Myeloproliferative disorders

Cryptogenic stroke Idiopathic--we cannot find a cause Accounts for ~25% of all strokes Thorough but negative evaluation Vs. Insufficient evaluation Diagnose only after comprehensive search for etiology

What Is An Adequate Work Up? History and examination Vascular Imaging EKG Telemetry in hospital Echocardiogram Routine lab tests

CT vs. MRI

CT vs MRI

Cerebral Vessels Carotid US / Transcranial Doppler CT Angiography MR Angiography Conventional Cerebral Angiography

CUS & TCD Non-invasive Least sensitive Tends to overestimate Nonetheless, still has a role in todays practice

CT vs MR Angiography Sensitivity & Specificity almost identical Patient profile dictates modality - Contrast vs Gad - Metal / implants - claustrophobia Certain sequences help in diagnosis mips / t1fat-sats Pick one

Conventional Cerebral Angiogram Non-invasive modalities do not nail it. Vasculitis RCVS Moya-Moya Hypo-perfusion

TTE Vs TEE Age-old question TEE is more sensitive for detection of : LAA thrombus PFO ASA Aortic arch plaque Valve vegetations Neurologist vs Cardiologist I need a TEE No Way!! Sebastiaan F.T.M. de Bruijn et al Stroke 2006

Who Should Get a TEE? Stroke in the young, age limit?? High suspicion for cardio-embolism, but no proven source Stroke in multiple vascular distributions History of cardiac disease

PFO A never ending story. PFO has low Risk for stroke recurrence Among 15 studies with medically treated PFO patients, the absolute rate of recurrent ischemic stroke was: 1.6 events per 100 person-years (95% CI: 1.1 2.1) Almekhlafi MA, et al. Neurology. 2009 Jul 14;73(2):89-97.

The Neurologist s Perspective on PFO & Stroke Biologically plausible interventions have failed numerous times in the past when tested rigorously : CLOSURE I, RESPECT, PC TRIAL. The risk of recurrent stroke on aspirin is low Percutaneous PFO closure is expensive, has a small but real risk of complication, and is unproven Off-label PFO closure is rampant and undermines studies

AAN Practice Parameter 2004 still holds in 2013 : Clinicians who encounter patients with cryptogenic stroke and PFO (and/or atrial septal aneurysm) should encourage them to consider participating in research protocols.

Mobile Cardiac Outpatient Telemonitoring (MCOT)

Penn Experience With MCOT 101 patients with cryptogenic stroke/tia 16% had afib detected AF Dx occurred a median of 7d(range 2-25)

Look Harder for Occult AFib About 15-20% of cryptogenic stroke pts have occult AF Older patients, women, and those with LA enlargement Up to 90% AF episodes are asymptomatic AF yield increased with longer monitoring duration >60% AF >30d after initiating monitoring Unknown optimal duration Treatment options for AFib expanding

Stroke Labs Routine Fasting Lipid HbA1c PT/PTT/INR CBC CMP Specific Lumbar puncture Cardiac enzmes Rheumatologic work up SPEP / UPEP HB Electrophoresis Toxicology screen VDRL / FTA ESR

Hypercoagulabilty & Stroke Hypercoagulability should be suspected in patients with ischemic stroke who : < 50 years with no obvious cause of stroke History of multiple unexplained strokes Previous history of venous thrombosis Family history of thrombosis Abnormalities on routine screening coagulation tests

Hypercoagulable States Inherited Factor V Leiden Prothrombin gene mutation Anti-thrombin deficiency Protein C & S deficiencies Elevated homocysteine Dysfibrinogenemia Elevated Factor VIII levels Abnormal fibrinolytic system Sickle Cell disease Acquired Antiphospholipid antibody syndrome Supplemental estrogen use HIT Cancer Medications Central venous catheter Obesity Pregnancy

Hypercoagulable workup PT and PTT Protein C Protein S Antithrombin III activity Prothrombin gene mutations Factor V Leiden gene mutation Activated Protein C resistance Anticardiolipin antibodies (IgG and IgM) Beta2-glycoprotein I antibodies (IgG and IgM) Lupus anticoagulant tests dilute Russell viper venom time dilute activated PTT hexagonal phospholipid Homocysteine Factor VIII activity D-dimer Lipoprotein (a) MTHFR

CANCER Autopsy study of patients with cancer, 15% had cerebrovascular disease (7% had clinical symptoms) Arterial and venous infarcts Elevated D-dimer, DIC, non-bacterial thrombotic endocarditis Consider: CT CAP Biomarkers

When is enough, enough? Only when you find the answer, or else Its never enough!!!